基本信息
浏览量:615
职业迁徙
个人简介
He served as chair and chair emeritus of the Department of Defense Ovarian Cancer Research Program, chair of the Committee for Experimental Medicine of the Gynecologic Oncology Group, chair of the Translational Science Working Group of the Gynecologic Cancer Intergroup, and a member of the Gynecologic Cancer Steering Committee.
Dr. Birrer's Research
Recognized nationally and internationally as an expert in gynecologic oncology, Birrer’s primary research interest is in characterizing the genomics of gynecologic cancers to improve the clinical management of these diseases. Birrer has approximately 400 publications, including peer-reviewed manuscripts, book chapters and review articles.
Over 21,000 Americans will be diagnosed with ovarian cancer this year, and over 14,000 of these patients will succumb to this disease. 70% of patients with ovarian cancer initially respond to platinum-based chemotherapy, but during treatment, the tumors will become increasingly more resistant to this approach. Herein lies the need for the development of novel agents against platinum-resistant ovarian cancers. Dr. Michael Birrer will be focused on developing new types of drug models and molecular approaches to help create alternative forms of treatment for multiple types of ovarian cancers. While his primary focus will be on that of ovarian cancer, he hopes his research, and ongoing clinical trials, will also help in the development of new treatments for multiple types of cancers studied here at the Winthrop P. Rockefeller Cancer Institute. Dr. Birrer has also been chosen to lead the UAMS goal of achieving National Cancer Institute designation, and he has assembled a top notch team of doctors, oncologists, surgeons, and researchers to help him on this journey.
Dr. Birrer's Research
Recognized nationally and internationally as an expert in gynecologic oncology, Birrer’s primary research interest is in characterizing the genomics of gynecologic cancers to improve the clinical management of these diseases. Birrer has approximately 400 publications, including peer-reviewed manuscripts, book chapters and review articles.
Over 21,000 Americans will be diagnosed with ovarian cancer this year, and over 14,000 of these patients will succumb to this disease. 70% of patients with ovarian cancer initially respond to platinum-based chemotherapy, but during treatment, the tumors will become increasingly more resistant to this approach. Herein lies the need for the development of novel agents against platinum-resistant ovarian cancers. Dr. Michael Birrer will be focused on developing new types of drug models and molecular approaches to help create alternative forms of treatment for multiple types of ovarian cancers. While his primary focus will be on that of ovarian cancer, he hopes his research, and ongoing clinical trials, will also help in the development of new treatments for multiple types of cancers studied here at the Winthrop P. Rockefeller Cancer Institute. Dr. Birrer has also been chosen to lead the UAMS goal of achieving National Cancer Institute designation, and he has assembled a top notch team of doctors, oncologists, surgeons, and researchers to help him on this journey.
研究兴趣
论文共 751 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
The oncologistno. 3 (2023): 252-257
Cancer Treatment Reviews (2023): 102489-102489
Michael J. Birrer, Brandon Roane
Disaia and Creasman Clinical Gynecologic Oncologypp.489-505.e5, (2023)
Gynecologic oncology (2023): 119-129
Shrabanti Chowdhury,Jacob J. Kennedy,Richard G. Ivey,Oscar D. Murillo,Noshad Hosseini, Xiaoyu Song,Francesca Petralia,Anna Calinawan,Sara R. Savage, Anna B. Berry,Boris Reva,Umut Ozbek,
CELLno. 16 (2023): 3476-+
引用4浏览0引用
4
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn